PHASE-II TRIAL OF IFOSFAMIDE IN RECURRENT AND METASTATIC HEAD AND NECK-CANCER

被引：19

作者：

BUESA, JM ^{[1
]}

FERNANDEZ, R ^{[1
]}

ESTEBAN, E ^{[1
]}

ESTRADA, E ^{[1
]}

BARON, FJ ^{[1
]}

PALACIO, I ^{[1
]}

GRACIA, M ^{[1
]}

LACAVE, AJ ^{[1
]}

机构：

[1] INST ONCOL,SAN SEBASTIAN,SPAIN

来源：

ANNALS OF ONCOLOGY | 1991年 / 2卷 / 02期

关键词：

IFOSFAMIDE; RECURRENT HEAD AND NECK CANCER;

D O I：

10.1093/oxfordjournals.annonc.a057880

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thirty-six patients with recurrent carcinoma of the head and neck and no prior exposure to chemotherapy were treated with Ifosfamide. This drug was administered, concomitantly with Mesna, as a 24-hr infusion at a dose of 5-6.25 g/m2 every 3 weeks. Objective activity in 32 evaluable patients was 28% (9/32, 95% C.I. 17%-39%); 40% of patients had leukocyte values < 2000 mm3 and 6% platelets < 50 000 mm3. Nonhematologic toxicity consisted mainly of nausea/vomiting (66% greater-than-or-equal-to grade 2) and alopecia (80% greater-than-or-equal-to grade 2). The activity encountered warrants further studies with this drug in head and neck cancer.

引用

页码：151 / 152

页数：2

共 5 条

[1] IFOSFAMIDE - PHARMACOLOGY, SAFETY AND THERAPEUTIC POTENTIAL [J].

BRADE, WP ;

HERDRICH, K ;

VARINI, M .

CANCER TREATMENT REVIEWS, 1985, 12 (01) :1-47

[2]

CERVELLINO JC, 1989, 5TH EUR C CLIN ONC L

[3]

MILLION RR, 1989, CANCER PRINCIPLES PR, P488

[4]

PAI VR, 1989, 5TH EUR C CLIN ONC L

[5] IFOSFAMIDE IN ADVANCED HEAD AND NECK-CANCER - A PHASE-II STUDY OF THE ROTTERDAM-COOPERATIVE-HEAD-AND-NECK-CANCER-STUDY-GROUP [J].

VERWEIJ, J ;

ALEXIEVAFIGUSCH, J ;

DEBOER, MF ;

REICHGELT, B ;

STOTER, G .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (04) :795-796

← 1 →